Epoetin-β and Cancer Treatment: A Meta-Analysis
Author Information
Author(s): Aapro M, Scherhag A, Burger H U
Primary Institution: Institut Multidisciplinaire d'Oncologie, Clinique de Genolier
Hypothesis
Does treatment with epoetin-β affect survival, tumor progression, and thromboembolic events in cancer patients?
Conclusion
Epoetin-β does not negatively impact survival, tumor progression, or thromboembolic event-related mortality in cancer patients when used according to guidelines.
Supporting Evidence
- Epoetin-β did not show a statistically significant effect on mortality compared to control.
- There was a trend for a beneficial effect on tumor progression in patients with low baseline hemoglobin.
- An increased frequency of thromboembolic events was observed with epoetin-β compared to control.
Takeaway
This study looked at whether a drug called epoetin-β helps cancer patients live longer or feel better. It found that it doesn't hurt their chances of survival or make their cancer worse.
Methodology
This meta-analysis included 12 randomized controlled studies evaluating the effects of epoetin-β on overall survival, disease progression, and thromboembolic events in cancer patients.
Potential Biases
Some studies had baseline imbalances and protocol violations that could affect the results.
Limitations
Most studies had short follow-up periods and were primarily designed to assess efficacy in anemia correction rather than survival or tumor progression.
Participant Demographics
65% of participants had solid tumors and 35% had nonmyeloid hematological malignancies.
Statistical Information
P-Value
0.355
Confidence Interval
95% CI: 0.87, 1.46
Statistical Significance
p=0.355
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website